Cabaletta Bio
biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. .
Launch date
Employees
Market cap
CAD274m
Enterprise valuation
CAD7m (Public information from Sep 2024)
Share price
$4.7 CABA
Radnor Township Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 5.6m | 2.5m |
| % growth | - | - | - | - | - | - | (55 %) |
| EBITDA | (33.8m) | (46.3m) | (54.1m) | (73.2m) | (123m) | (144m) | (166m) |
| % EBITDA margin | - | - | - | - | - | (2588 %) | (6648 %) |
| Profit | (33.3m) | (46.3m) | (53.0m) | (67.7m) | (114m) | (135m) | (159m) |
| % profit margin | - | - | - | - | - | (2423 %) | (6352 %) |
| EV / revenue | - | - | - | - | - | 36.6x | 32.2x |
| EV / EBITDA | -5.7x | 0.3x | -3.0x | -10.0x | -0.9x | -1.4x | -0.5x |
| R&D budget | 21.4m | 32.5m | 39.3m | 55.4m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$38.0m | Series A | ||
* | $50.0m | Series B | |
| N/A | N/A | IPO | |
* | N/A | N/A | Post IPO Equity |
* | $35.0m | Post IPO Equity | |
* | N/A | $87.0m | Post IPO Equity |
| Total Funding | CAD120m | ||
Related Content
Recent News about Cabaletta Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.